Vaccines against Tuberculosis: Where Are We and Where Do We Need to Go?

Ottenhoff, Tom H. M.; Kaufmann, Stefan H. E.

doi:10.1371/journal.ppat.1002607

Item

ITEM ACTIONSEXPORT

Add to Basket

Local TagsRelease HistoryDetailsSummary

Released

Journal Article

Vaccines against Tuberculosis: Where Are We and Where Do We Need to Go?

MPS-Authors

/persons/resource/persons81969

Kaufmann, Stefan H. E.
Department of Immunology, Max Planck Institute for Infection Biology, Max Planck Society;

External Resource

No external resources are shared

Fulltext (restricted access)

There are currently no full texts shared for your IP range.

Fulltext (public)

PLoS_Pathogens_2012_8_e1002607.pdf
(Publisher version), 248KB

Supplementary Material (public)

There is no public supplementary material available

Citation

Ottenhoff, T. H. M., & Kaufmann, S. H. E. (2012). Vaccines against Tuberculosis: Where Are We and Where Do We Need to Go? PLoS Pathogens, 8(5): e1002607. doi:10.1371/journal.ppat.1002607.

Cite as: https://hdl.handle.net/11858/00-001M-0000-000E-BDF3-C

Abstract

In this review we discuss recent progress in the development, testing, and clinical evaluation of new vaccines against tuberculosis (TB). Over the last 20 years, tremendous progress has been made in TB vaccine research and development: from a pipeline virtually empty of new TB candidate vaccines in the early 1990s, to an era in which a dozen novel TB vaccine candidates have been and are being evaluated in human clinical trials. In addition, innovative approaches are being pursued to further improve existing vaccines, as well as discover new ones. Thus, there is good reason for optimism in the field of TB vaccines that it will be possible to develop better vaccines than BCG, which is still the only vaccine available against TB.